IDH1 and IDH2 mutations as friends and foes in human cancer
published: May 7, 2018, recorded: March 2018, views: 1618
Report a problem or upload filesIf you have found a problem with this lecture or would like to send us extra material, articles, exercises, etc., please use our ticket system to describe your request and upload the data.
Enter your e-mail into the 'Cc' field, and we will keep you updated with your request's status.
The enzyme isocytrate dehydrogenase IDH is very important in carbohydrate metabolism, and when mutated in cancer cells, the metabolic pathway is drastically altered. Somatic mutations in IDH1/2 occur in 20% of patients with myeloid neoplasms, including glioma, melanoma, prostate cancer and acute myeloid leukemia. Cancer patients with IDH1/2 mutations have a relatively prolonged survival compared with IDH1/2 wild-type counterparts. The underlying molecular mechanism in various subtypes of cancer have been demonstrated to also involve altered redox homeostasis and reduced DNA damage repair. Furthermore, the ongoing clinical trials in which we repurpose already-approved and off-patent drugs for the treatment of IDH1/2-mutated cancers will be discussed.
Link this pageWould you like to put a link to this lecture on your homepage?
Go ahead! Copy the HTML snippet !